Follow up is still insufficient to assess...
 

the impact of adjuvent therapy to early stage disease. I believe we may
see increase in these stats in the near future.

Each day we are getting closer!

http://www.medicalnewstoday.com/medi...=67800&nfid=al

Regards,
Jean

Good article Jean. This supports many of the trial presentations on the use of Taxol in early bc (especially those that specifically show the use of Taxol as being extremely important and useful after 4 doses of AC in Her2+ bc). It's superiority is amazing when looking at the raw data and having the populations split out (ie: Her2 vs non-Her2 (but hormone + only)).

Yes Becky I am quite excited over the article. I really believe we are on the
right track and will come in on the "FINISH" line. Yahoo...

Jean

Always encouraging to read good news.


Mary Jo